52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Elektrofi, Takeda Enter Agreement On Elektrofi's Formulation Tech
Takeda Pharmaceutical- Phase 2 Elektra Study Of Soticlestat Meets Primary Endpoint
Takeda & Novavax Announce Collaboration For Novavax' COVID-19 Vaccine Candidate In Japan
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
4F, 2-1-1, Nihombashihon-cho
Independent Chairman of the Executive Board
President, Chief Executive Officer, Representative Director
Chief Financial Officer, Director
President of Japan Pharma Business Unit, President of Subsidiary, Director
Andrew S. Plump
President of Research & Development, Director
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
An experimental COVID-19 therapy using blood plasma, developed by Japan's Takeda Pharmaceutical Co and its partners, is scheduled to begin a late-stage clinical trial after initial delays.
A federal appeals court on Thursday revived a lawsuit filed by a Takeda Pharmaceutical Co unit alleging one of its patents was infringed by the Genentech hemophilia drug Hemlibra, reversing one of its own judges who was sitting in a lower court.
Takeda Pharmaceutical Co said on Monday it would sell its Japanese consumer healthcare business to U.S. buyout fund Blackstone Group, as it aims to focus on developing drugs for unmet medical needs and rare diseases.
Takeda Pharmaceutical Co has agreed to sell its Japanese consumer healthcare business to U.S. investment fund Blackstone Group for 242 billion yen ($2.3 billion), Japan's largest drugmaker said on Monday.
Japan's Takeda Pharmaceutical Co Ltd <4502.T> is making final arrangements to sell its domestic over-the-counter (OTC) business to U.S. investment fund Blackstone Group Inc <BX.N>, Kyodo News reported on Wednesday.
Takeda Pharmaceutical will manufacture and sell up to 250 million doses of Novavax Inc's COVID-19 vaccine candidate in Japan every year, the two companies said on Friday.
* NOVAVAX AND TAKEDA ANNOUNCE COLLABORATION FOR NOVAVAX' COVID-19 VACCINE CANDIDATE IN JAPAN
Japan's Takeda Pharmaceutical Co <4502.T> on Friday raised its full-year profit forecast as it refocuses on its core prescription drug businesses following its $59 billion takeover of Shire Plc last year.
Takeda Pharmaceutical Co <4502.T> is looking to cut sales jobs in Japan in its latest restructuring effort, as it overhauls domestic business following its $59 billion purchase of Shire Plc, sources familiar with the company's plans said.
Takeda Pharmaceutical Co is looking to cut sales jobs in Japan in its latest restructuring effort, as it overhauls domestic business following its $59 billion purchase of Shire Plc, sources familiar with the company's plans said.
Takeda Pharmaceutical is showing signs of recovery after a mega-merger, but shareholders keep feeling the pain. Some 18 months after completing a $62 billion takeover of Irish rival Shire, the Japanese drugmaker may sell another business to further pare debt. Promised cost...
* TAKEDA PARTNERS WITH TWIST BIOSCIENCE TO EXPAND BIOLOGICS DISCOVERY CAPABILITIES Source text for Eikon: Further company coverage:
* TAKEDA PHARMACEUTICAL CO - FILES FOR OFFERING OF 4-PART, SENIOR NOTES OF UP TO $7 BILLION - SEC FILING Source text for Eikon: [ID: https://bit.ly/2YJG363] Further company coverage:
Takeda Pharmaceutical Co Ltd <4502.T> said on Monday it anticipates an operating loss of about $200 million related to Novartis AG's decision to withdraw a marketing application for the dry-eye drug Xiidra.
* TAKEDA PHARMACEUTICAL - FILES PRELIM PROSPECTUS SUPPLEMENT RELATED TO USD DENOMINATED FOUR-PART SENIOR NOTES OFFERING; SIZE NOT DISCLOSED Source text (https://bit.ly/3fXtUQM) Further company coverage:
* TAKEDA PHARMACEUTICAL SAYS IT FILES PRELIM PROSPECTUS SUPPLEMENT RELATED TO FOUR-PART SENIOR NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text (https://bit.ly/2Nzc6zb) Further company coverage:
* TAKEDA PHARMACEUTICAL CO LTD FILES FOR DEBT SHELF; SIZE NOT DISCLOSED - SEC FILING Source text: https://bit.ly/31ddjV9 Further company coverage:
Blackstone, Bain Capital and Taisho Pharmaceutical are among the final bidders for Takeda Pharmaceutical's <4502.T> consumer drug business in Japan, a deal that could be worth up to 400 billion yen ($3.7 billion), three people familiar with the deal said.
* NEUROCRINE BIOSCIENCES AND TAKEDA ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE POTENTIAL THERAPIES FOR PSYCHIATRIC DISORDERS
Takeda Pharmaceutical Co Ltd <4502.T> has agreed to sell a portfolio of over-the-counter and prescription drugs marketed in the Asia Pacific region to South Korea's Celltrion Inc <068270.KS> for $278 million, it said on Thursday
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.